<DOC>
	<DOC>NCT00633997</DOC>
	<brief_summary>This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients with type 2 diabetes.</brief_summary>
	<brief_title>Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Healthy volunteers and patients with type 2 diabetes Nonsmoking, Caucasian and African American, male and female (postmenopausal, surgically sterile or using doublebarrier method of contraception) subjects between 30 and 65 years of age (inclusive) Type 2 diabetics on metformin and/or sufonylurea History of type 1 diabetes or insulin use History of coagulation abnormalities History of abnormal heart conditions Pregnancy or breastfeeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>